TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
Highlights Newly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture Expands the Company's ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-15 5:00 PM EST | TempraMed Technologies Ltd
CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
Houston, Texas--(Newsfile Corp. - December 15, 2025) - Dante Picazo, CEO of Cannabis Bioscience International Holdings, Inc. trading under ticker symbol CBIH (OTCID: CBIH), provided the following update in light of recent reports suggesting that President Donald Trump may issue an executive order aimed at accelerating the federal process of rescheduling cannabis from Schedule I to Schedule III. CBIH believes that, if the process moves forward, it could represent one of the most conseque
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-15 7:00 AM EST | Cannabis Bioscience International Holdings
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that c
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-12 7:51 PM EST | NervGen Pharma Corp.
InMed Provides Update on BayMedica Commercial Business
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement. Recently, H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension
Biotechnology, Pharmaceuticals
2025-12-12 5:31 PM EST | InMed Pharmaceuticals
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 (&#
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-12 5:00 PM EST | Theralase Technologies Inc.
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, is pleased to announce that Thomas Smeenk
Biotechnology, Pharmaceuticals, Health
2025-12-11 9:40 AM EST | Hemostemix Inc.
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 663,000 vest immediately and
Biotechnology, Pharmaceuticals, Health
2025-12-11 8:57 AM EST | Hemostemix Inc.
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for develo
2025-12-11 8:00 AM EST | BetterLife Pharma Inc.
Herbal Dispatch Unveils Strategic Business Plan for 2026 to Drive Sustainable Growth and Enhance Shareholder Value
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leading cannabis e-commerce and distribution platform, today announced its comprehensive Strategic Business Plan for 2026. This plan builds on the Company's robust historical performance, aiming to significantly accelerate revenues while improving gross margins and EBITDA. The plan outlines four key
Pharmaceuticals, Cannabis, Cannabis Dispensary
2025-12-11 3:01 AM EST | Herbal Dispatch Inc.
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce that, further to its news release o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-10 8:00 PM EST | Quantum BioPharma Ltd.
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost diabetes researchers, to its Scientific Advisory Board. His appointment further enhances TempraMed's scientific foundation as the Company
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-10 5:00 PM EST | TempraMed Technologies Ltd
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved all matters presented at the Company's annual general meeting of the shareholders held today, as follows:
Biotechnology, Pharmaceuticals, Health
2025-12-10 4:30 PM EST | Defence Therapeutics Inc.
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, with ACP
Biotechnology, Pharmaceuticals, Health
2025-12-10 11:17 AM EST | Hemostemix Inc.
Custom Health Announces First Closing of Brokered Private Placement of Subscription Receipts for Gross Proceeds of US$9.6M
Kelowna, British Columbia--(Newsfile Corp. - December 9, 2025) - Custom Health Inc. ("Custom Health" or the "Company"), a vertically integrated, tech-enabled care platform, is pleased to announce that Custom FundCo Inc. ("FundCo") has completed the first closing (the "First Closing") of its previously announced brokered private placement financing of subscription receipts (the "Offering") being conducted in connection with the Company's proposed busin
Technology, Pharmaceuticals, Health
2025-12-09 9:40 AM EST | Custom Health
Telescope Innovations Installs Korea's First Self-Driving Lab for Pharma R&D and Education
HIGHLIGHTS Telescope Innovations' installation of Korea's first Self-Driving Lab for pharmaceutical research completed just three weeks after contract signing Project facilitated by collaboration with the Acceleration Consortium (AC) and supported on site by two-time Chemistry Nobel Laureate Prof. Barry Sharpless Successful SDL delivery demonstrates Telescope's growing commercial momentum, positioning Telescope and the AC to expand SDL adoption across phar
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-09 8:00 AM EST | Telescope Innovations Corp.
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-08 5:00 PM EST | TempraMed Technologies Ltd
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-05 5:00 PM EST | TempraMed Technologies Ltd
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee: On-boarding of all new patients entering Hemostemix treatment programs;
Biotechnology, Pharmaceuticals, Health
2025-12-04 9:10 AM EST | Hemostemix Inc.
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprie
Biotechnology, Pharmaceuticals, Health
2025-12-04 7:00 AM EST | PreveCeutical Medical Inc.
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey. Defence
Biotechnology, Pharmaceuticals, Health
2025-12-04 3:15 AM EST | Defence Therapeutics Inc.